Phoenix 24
The environmental footprint of healthcare does not end when treatment does.
Uppsala
Researchers across Sweden, Finland, Lithuania and Latvia are examining how medicines such as diclofenac, ibuprofen, paracetamol and carbamazepine are entering the Baltic Sea and accumulating in an already vulnerable ecosystem. Their work suggests that reducing pharmaceutical pollution will require more than improving wastewater treatment. It will also require changes in how medicines are prescribed, consumed and discarded.
The Baltic is particularly exposed because it is a semi enclosed sea surrounded by nine countries and already burdened by industrial chemicals, agricultural runoff, microplastics and historical contamination. Pharmaceutical residues add another layer of pressure. Wastewater treatment plants alone are estimated to release around 1,800 tonnes of pharmaceutical substances into the Baltic each year.
Many treatment facilities are still not equipped with an advanced fourth stage capable of removing these contaminants. Even where medicines are used correctly, part of the active substance can pass through the human body and enter wastewater. Some compounds then persist for long periods. Carbamazepine, for example, breaks down so slowly that researchers say its environmental half life can extend to roughly three and a half years.
The concern is less about people being directly harmed by swimming in the sea and more about the effects on aquatic organisms. Synthetic hormones can alter reproductive development in fish and amphibians, while painkillers may reduce the energy available to Baltic blue mussels for normal metabolism and growth. Pharmaceutical contamination may also contribute to antimicrobial resistance, creating a problem that extends beyond marine ecology.
Researchers are therefore looking upstream. If several medicines are clinically appropriate, doctors could eventually consider environmental impact as one factor in prescribing decisions. That does not mean withholding necessary treatment. It means integrating ecological consequences into rational prescribing when equivalent therapeutic options exist.
Unused medicines represent another preventable pathway. Returning them to pharmacies rather than flushing them down toilets or placing them in household waste can significantly reduce environmental release. Rising return rates in countries such as Lithuania are encouraging, but they also raise another question: why were so many medicines prescribed but never used?
The Baltic case reveals a broader challenge for modern healthcare. Medicines can improve or save human lives while simultaneously creating environmental consequences after they leave the patient.
The next stage of sustainable medicine may therefore depend not only on developing safer drugs, but on managing their entire life cycle from prescription to disposal.
The visible and the hidden, in context.